Medication info

Cyclorus Tablets (Acyclovir)

Prescription medicationTabletIntravenous injectionExpired
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Taegeuk Pharmaceutical Co., Ltd.
Appearance
Light blue round tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 200 tablets/bottle
Approval status
Expired

MFDS item code 201906823 · Approved 2019.09.25

This product's status changed to Expired on 2024.09.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended for severe initial infections. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer as soon as possible after infection; in recurrent cases, administration is preferred at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infection in patients with normal immune function 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) The dose may subsequently be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued and reassessed every 6 ~ 12 months. 3. Prevention of herpes simplex infection in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infection 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunocompromise or gastrointestinal malabsorption. 3) Administer as soon as possible after infection; earlier treatment produces better results. ○ Patients with renal impairment Since patients with renal impairment are more susceptible to adverse reactions involving the neuropsychiatric system, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infection The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer this drug at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infection 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.
Child administration
○ Children 1. Treatment of herpes simplex infection and prevention of herpes simplex infection in immunocompromised patients 1) Age 2 years and older: Same as adults. 2) Under 2 years: Administer 1/2 of the adult dose. 3) Reliable data are not yet available for the prevention of herpes simplex virus infection in patients with normal immune function. 2. Treatment of chickenpox in children 2 years of age and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Ingredients

Manufacturer
Taegeuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children

  • Genital herpes
  • herpes simplex virus infection
  • shingles virus infection
  • acute situational pain
  • chickenpox
View approved original text

This medication is used in the treatment and prevention of herpes virus infections, including primary and recurrent genital herpes. It is also effective in treating shingles viral infections, helping particularly to alleviate acute pain. It is utilized for the treatment of chickenpox in children over 2 years old. Thus, it is widely used for the treatment of various viral infections.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended for severe initial infections. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer as soon as possible after infection; in recurrent cases, administration is preferred at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infection in patients with normal immune function 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) The dose may subsequently be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued and reassessed every 6 ~ 12 months. 3. Prevention of herpes simplex infection in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infection 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunocompromise or gastrointestinal malabsorption. 3) Administer as soon as possible after infection; earlier treatment produces better results. ○ Patients with renal impairment Since patients with renal impairment are more susceptible to adverse reactions involving the neuropsychiatric system, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infection The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer this drug at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infection 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.

Child administration

○ Children 1. Treatment of herpes simplex infection and prevention of herpes simplex infection in immunocompromised patients 1) Age 2 years and older: Same as adults. 2) Under 2 years: Administer 1/2 of the adult dose. 3) Reliable data are not yet available for the prevention of herpes simplex virus infection in patients with normal immune function. 2. Treatment of chickenpox in children 2 years of age and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Precautions

This medication should not be used in patients who are allergic to this medication or its components or have experienced hypersensitivity reactions. Patients with poor kidney function may be at higher risk for neuropsychiatric side effects when using this medication. Patients with impaired liver function should also be cautious as liver function may worsen when using this medication. Children, especially infants and young children, require careful monitoring when using this medication, and it should only be administered at the minimum dose necessary when needed. Elderly patients are also at increased risk for side effects due to potential declines in kidney function, so dosage and intervals should be adjusted and used cautiously. Rarely, serious allergic reactions such as anaphylactic shock may occur when using this medication, so if symptoms such as low blood pressure, difficulty breathing, or chest tightness appear, usage should be discontinued immediately and medical assistance sought. Skin rashes, fever, blisters, and urticaria may occur, and if such symptoms develop, treatment should be stopped and the patient should receive appropriate care. This medication can cause various skin side effects such as hair loss, dermatitis, and severe skin conditions, so caution is necessary. Mental issues, confusion, hallucinations, seizures, drowsiness, tremors, insomnia, and other neurological side effects may occur, particularly in elderly or patients with reduced kidney function. Renal complications such as renal failure, hematuria, and proteinuria may occur, therefore, kidney function should be monitored periodically. Blood-related side effects such as leukopenia, anemia, and bleeding may arise, and if abnormal symptoms occur, consultation with medical personnel is necessary. Liver function abnormalities or symptoms of hepatitis and jaundice should be carefully monitored. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain may occur, and if symptoms are severe, treatment should be stopped and appropriate measures taken. Sufficient hydration is very important during treatment with this medication, especially to prevent dehydration during high-dose administration. To enhance treatment efficacy, administration of this medication should begin within 5 days for shingles after the onset of skin symptoms, and within 3 days for chickenpox. For patients with weakened immunity, intravenous therapy may be considered. Patients should be cautious when engaging in activities such as driving or operating machinery during treatment, especially those with compromised kidney function, as consciousness disturbances may occur. Interactions may arise when used in conjunction with other medications, so it is essential to inform healthcare providers of any other medications currently being taken. Women who are pregnant or may become pregnant should discuss potential risks to the fetus with their doctor when using this medication, and breastfeeding should be discontinued if using during lactation. In cases of overdose, severe neurological symptoms and kidney damage may occur, so dosage must be strictly adhered to and immediate medical attention should be sought in case of overdose.

Side effects

  • Anaphylactic shock
  • anaphylactic-like reaction
  • hypotension
  • dyspnea
  • chest tightness
  • phototoxic reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 118 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration disorder
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • convulsions
  • drowsiness
  • tremors
  • agitation
  • amnesia
  • insomnia
  • anxiety
  • soliloquy
  • paresthesia
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • elevated BUN
  • increased serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • bleeding
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • soft stools
  • epigastric pain
  • stomachache
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • malaise
  • general fatigue
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleurisy
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste impairment
  • hair loss
  • sweating
  • hyponatremia
  • hypoproteinemia
  • elevated total cholesterol levels
  • elevated triglyceride levels
  • increased serum potassium levels
  • decreased serum albumin levels
  • anxiety
  • coma
  • convulsions
  • drowsiness
  • confusion
  • hallucinations
  • agitation
  • seizures
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is important to store it at a temperature between 1 and 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Light blue round tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.